Each day, 10,000 Americans turn 65 and will be at the greatest risk of age-related eye disease and vision loss.
Dan Ignascewski
Executive Director, National Alliance for Eye and Vision Research (NAEVR)
The prevalence of eye diseases like age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and cataracts is expected to rise significantly. This surge underscores the urgent need for increased funding and research to develop better treatments and improve the quality of life for millions of Americans. The annual economic impact of major vision problems among the adult population was estimated to exceed $182 billion in 2021, and that’s expected to rise to $373 billion by 2050. The distinct and dedicated efforts of the National Eye Institute (NEI) are crucial for addressing the unique challenges and needs of vision health.
Furthermore, the economic impact of vision loss in an aging population is staggering and poses a significant burden on taxpayers. Vision impairment and blindness lead to increased healthcare costs, loss of productivity, and a greater need for social services. Only through dedicated research can we develop effective prevention strategies, innovative treatments, and cures that will mitigate these expenses. Vision research is not just a medical necessity; it is an economic imperative to reduce the financial strain on our healthcare system and society at large.
Age-related macular degeneration (AMD)
AMD affects the macula, the part of the retina responsible for central vision. It is the leading cause of vision loss in Americans aged 50 and older. The NEI estimates that by 2050, the number of people with AMD will reach nearly 6 million. Despite advancements in treatment, there is no cure for AMD, and ongoing research is crucial to finding more effective therapies.
Glaucoma
Glaucoma, often called the “silent thief of sight,” gradually damages the optic nerve and can lead to irreversible vision loss. It affects over 3 million Americans, with the prevalence expected to increase as the population ages. Early detection and treatment are essential, yet many remain undiagnosed until significant vision loss occurs. Enhanced research funding can lead to better diagnostic tools and treatments to prevent glaucoma-related blindness.
Diabetic retinopathy
Diabetic retinopathy, a complication of diabetes, affects the blood vessels in the retina and can lead to blindness if left untreated. With the rising incidence of diabetes, the number of Americans with diabetic retinopathy is expected to increase from 7.7 million in 2010 to 14.6 million by 2050. Research is vital to developing innovative treatments and preventive measures to combat this sight-threatening disease.
Cataracts
Cataracts, characterized by the clouding of the eye’s lens, are a leading cause of vision impairment among the elderly. The NEI projects that by 2050, the number of Americans with cataracts will double to approximately 50 million. While cataract surgery is highly effective, ongoing research is needed to improve surgical outcomes and develop non-surgical treatments.
National Alliance for Eye and Vision Research (NAEVR) plays a pivotal role in advocating for increased funding and providing educational resources. Vision impairment and blindness pose significant challenges to an aging population. Increased funding for the NEI and other research institutions is essential to develop new treatments, improve existing ones, and ultimately find cures for these debilitating eye diseases. By prioritizing funding, we can support the scientific advancements necessary to tackle the growing prevalence of eye diseases and ensure that our aging population can maintain their vision and quality of life.
